Corindus

About Corindus

Corindus Vascular Robotics, now operating as Siemens Healthineers Endovascular Robotics, specializes in the development of robotic-assisted systems for vascular interventions. The company was founded in Israel in 2002 by interventional cardiologist Rafael Beyar and his student, Tal Wenderow. Their objective was to leverage robotics for the remote manipulation of coronary guidewires and balloon/stent catheters. After its founding, the company relocated its headquarters to Waltham, Massachusetts, to continue its growth. A significant milestone was achieved when the company went public in August 2014, trading under the ticker symbol CVRS. The company's trajectory culminated in its acquisition by Siemens Healthineers in October 2019 for approximately $1.1 billion, a move designed to combine Siemens' imaging and digital platforms with Corindus's robotic technology.

The core of Corindus's business is the design, manufacture, and sale of its robotic-assisted platforms to hospitals and medical institutions. The company operates in the surgical devices market, providing tools for interventional cardiologists, radiologists, and vascular surgeons performing minimally invasive procedures. Its flagship product, the CorPath GRX System, is the second generation of its robotic platform. This system is engineered to enhance precision and workflow in vascular procedures. A key feature is its radiation-shielded interventional cockpit, which allows physicians to operate from a seated position, away from the radiation exposure typical in catheterization labs. The physician uses a console with joysticks and a high-resolution monitor to control guidewires and catheters with sub-millimeter precision. This technology aims to standardize procedures, reduce variability between operators, and potentially shorten procedure times. The CorPath GRX System supports coronary, peripheral vascular, and neurovascular interventions. It received FDA clearance for both coronary and peripheral vascular interventions, marking it as a significant device in the field.

The acquisition by Siemens Healthineers has integrated Corindus into a larger medical technology portfolio, aiming to accelerate the development of image-guided robotic solutions. The business now functions as the Endovascular Robotics division of Siemens Healthineers. This strategic integration seeks to pair Corindus's robotic precision with Siemens' advanced imaging, digital, and artificial intelligence tools to improve patient outcomes in the treatment of cardiovascular and peripheral diseases. The combined technologies have the potential to reduce procedural variability, enhance efficiency, and expand patient access to advanced care.